文献速递临床试验与 GCP基础与转化研究

选择性JAK1抑制剂非戈替尼治疗甲氨蝶呤反应不足的活动性类风湿关节炎患者的疗效与安全性:非戈替尼与托珠单抗对比的临床指标及肌肉骨骼超声评估研究(TRANSFORM研究):一项随机、开放标签、平行组、多中心、非劣效性临床试验的研究方案

Efficacy and safety of selective JAK 1 inhibitor filgotinib in active rheumatoid arthritis patients with inadequate response to methotrexate: comparative study with filgotinib and tocilizumab examined by clinical index as well as musculoskeletal ultrasound assessment (TRANSFORM study): study protocol for a randomized, open-label, parallel-group, multicenter, and non-inferiority clinical trial.
PubMed 文献 · Trials · 2023-03-03

本研究为多中心随机开放标签平行组非劣效性临床试验,计划纳入400例甲氨蝶呤治疗下至少中度疾病活动的类风湿关节炎患者,1:1随机接受非戈替尼单药或皮下托珠单抗单药治疗,随访52周。主要终点为第12周达到ACR50应答的患者比例,次要终点为肌肉骨骼超声评分较基线的变化,并综合分析血清生物标志物。研究预期非戈替尼单药疗效非劣效于托珠单抗单药。

要点

  • 非戈替尼单药对比托珠单抗单药治疗MTX反应不足的RA患者,主要终点为第12周ACR50应答率。
  • 研究采用肌肉骨骼超声评估关节水平疾病活动,并综合分析血清细胞因子和趋化因子等生物标志物。
  • 试验计划纳入400例患者,1:1随机分组,随访52周,为非劣效性设计。

核心结论

  • 研究结果预期显示非戈替尼单药治疗对MTX反应不足的RA患者的疗效非劣效于托珠单抗单药治疗。

研究设计与样本

  • 本研究为干预性、多中心、随机、开放标签、平行组、非劣效性临床试验,随访52周。
  • 计划纳入400例在MTX治疗期间至少中度疾病活动的RA患者,按1:1比例随机分配至非戈替尼单药组或从MTX转换为皮下托珠单抗单药组。

主要发现

  • 主要终点为第12周达到美国风湿病学会50(ACR50)应答的患者比例。
  • 次要终点为肌肉骨骼超声(MSUS)评分较基线的变化。
  • 将综合分析血清多种生物标志物水平,如细胞因子和趋化因子。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Administration of Janus kinase (JAK) inhibitors and biological disease-modifying antirheumatic drugs has dramatically improved even the clinical outcomes in patients with rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX). Dysregulation of JAK-STAT pathways via overproduction of cytokines, such as interleukin-6, is involved in the pathogenesis of RA. Filgotinib is a selective JAK1 inhibitor pending approval for use in RA. By inhibition of the JAK-STAT pathway, filgotinib is effective in suppressing disease activity and preventing the progression of joint destruction. Similarly, interleukin-6 inhibitors such as tocilizumab also inhibit the JAK-STAT pathways by inhibition of interleukin-6 signaling. We present the protocol for a study that will evaluate whether the effectiveness of filgotinib monotherapy is non-inferior to that of tocilizumab monotherapy in RA patients with an inadequate response to MTX. METHODS: This study is an interventional, multicenter, randomized, open-label, parallel-group, and non-inferiority clinical trial with a 52-week follow-up. Study participants will be 400 RA patients with at least moderate disease activity during treatment with MTX. Participants will be randomized in a 1:1 ratio to administer filgotinib monotherapy or subcutaneous tocilizumab monotherapy switched from MTX. We will evaluate disease activity by measuring clinical disease activity indices and by using musculoskeletal ultrasound (MSUS). The primary endpoint is the proportion of patients who achieve an American College of Rheumatology 50 response at week 12. Secondary endpoints are changes from baseline in the MSUS scores. We will also comprehensively analyze serum levels of multiple biomarkers, such as cytokines and chemokines. DISCUSSION: The study results are expected to show the non-inferiority of the effectiveness of filgotinib monotherapy to that of tocilizumab monotherapy in RA patients with inadequate response to MTX. The strength of this study is its prospective evaluation of therapeutic efficacy using not only clinical disease activity indices, but also MSUS, which accurately and objectively evaluates disease activity at the joint level among patients drawn from multiple centers with a standardized evaluation by MSUS. We will evaluate the effectiveness of both drugs by integrating multilateral assessments-clinical disease activity indices, MSUS findings, and serum biomarkers. TRIAL REGISTRATION: Japan Registry of Clinical Trials ( https://jrct.niph.go.jp ) jRCTs071200107. Registered on March 3, 2021. CLINICALTRIALS: gov NCT05090410. Registered on October 22, 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Shimizu T, Kawashiri SY, Morimoto S, et al. Efficacy and safety of selective JAK 1 inhibitor filgotinib in active rheumatoid arthritis patients with inadequate response to methotrexate: comparative study with filgotinib and tocilizumab examined by clinical index as well as musculoskeletal ultrasound assessment (TRANSFORM study): study protocol for a randomized, open-label, parallel-group, multicenter, and non-inferiority clinical trial. Trials. 2023. PMID: 36869356. doi:10.1186/s13063-023-07176-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。